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treatment of chronic spinal cord injury (SCI) have been carried out all over the world.
However, their safety and efficacy have not been basically evaluated. Moreover, there
are no uniform standards laid out for the use of optimal source, transplantation method
and the dosage of OECs.
Objective: This study evaluated the source, dose, and route of transplantation of
OECs for the treatment of chronic SCI.
Methods: PubMed, Cochrane Library, EMBASE, CNKI, and Wanfang Data were
searched for the clinical studies of OECs in the treatment of chronic SCI on July 2018.
Results: A total of 30 articles on OECs transplantation for chronic SCI were selected
for comprehensive evaluation of OECs sources, doses, and transplantation methods.
The efficacy of OECs in the treatment of chronic SCI was evaluated using Review
Manager 5.3.
Conclusion: Fetal OECs are the primary source of cells for the treatment of chronic
SCI in OECs, with standardized cell-culture and quality-control processes. Fetal
OECs can significantly improve the neurological function of patients with chronic
SCI. It is an ideal cell therapy for neurorestoration. However to explore more precise
and minimally invasive treatment options are required in the future.

1

Introduction

Spinal cord injury (SCI) is the most serious complication
of spinal injury and often leads to severe neurological
dysfunction below the lesioned segment. The incidence
of SCI is increasing year by year, and the annual
increase of SCI patients is about 500,000 worldwide
[1]. It has been previously thought that in the sequela
of SCI, the nerve self-repair function disappears,
leading to permanent neurological dysfunction.
Fortunately, after years of unrelenting efforts by

researchers and clinicians, neurorestoration has become
a reality. In 2014, 31 experts from 20 countries reached
a consensus [2]: neurorestorative strategies with positive
preclinical results have been translated into clinical
studies, and cell therapy has emerged as one of the
most highly regarded neurorestorative strategies.
In 2017, Assinck et al. [3] proposed that olfactory
ensheathing cells (OECs) are one of the ideal cells for
repairing SCI. OECs are a class of mature functionally
differentiated glial cells that functions between Schwann
cells and oligodendrocytes. These OECs have many
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neurorestorative functions including neurotrophic
effects [4], ability to inhibit gliosis and scar formation
[5], ensheathing capacity [6], immune regulation [7],
and strong mobility [8]. Huang first began the clinical
study of OECs transplantation for the treatment of SCI
in the world as early as 2001. Subsequently, various
countries and regions have successively carried out
clinical researches on the OECs therapy.
Clinical Cell Therapy Guidelines for Neurorestoration
published in 2016 and 2018 [9, 10] have recommended
the safe doses of olfactory ensheathing cell and the
transplantation methods. However, there is no detailed
instruction for these factors provided in these two
guidelines.
In order to further understand the precise treatment
of SCI by OECs treatment, this study was based on
the source, dose and transplantation methods of OECs
in order to systematically evaluate the treatment
strategies of chronic SCI with OECs.

2
2.1

SCI clinical trials of OECs transportation
Search strategy

In July 2018, we searched for related clinical trials
in PubMed, Cochrane Library, EMBASE, CNKI, and
Wanfang Data. The search language is not limited. After
all possible studies were identified, their references
were screened for potential articles. The English
database search terms and retrieval methods are
shown in Table 1.
2.2

Trial identification and features

PubMed, EMBASE and Cochrane Library databases
were searched and 328 papers were included in this
study. After excluding duplicate literatures, retrospective literatures, case reports, reviews, animal
experiments and irrelevant literatures, a total of
30 clinical trials on OECs transplantation for SCI
published during 2002‒2014 were selected, which
include 6 Chinese and English literatures by manual
searching. The publication peaked in 2006 and declined
after 2011 (Fig. 1).
These 30 articles are from 4 different countries,
including 25 from China, 2 from Portugal, 2 from
Australia, and 1 from Poland. In addition, there is
only one RCT trial from China [11]. In the aspect of
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source of OECs, fetal OECs were used in all the
Chinese literatures except Rao’s. Autologous olfactory
mucosa (OMAs) were used in 2 trials from Portugal.
Autologous OECs were used in Australia and Poland.
2.3 Data extraction
Two researchers extracted data from 30 articles
including source, injection site, dose, maximum volume
of injection, injection target (Table 2).
2.4

Typical clinical trials

From 2001 to 2006, Lima et al. [34, 35] performed partial
scar repair and OMAs transplantation of SCI in 27
patients with chronic SCI. The results indicated that
OMA is feasible, relatively safe, and may be beneficial
for patients with chronic SCI when combined with
postoperative rehabilitation. They believe that one of
the keys to OMAs transplantation for chronic SCI is
that OMAs contain NSCs which repair nerve function
other than Schwann cells or OECs. But the fact is that
Lima currently reports a small sample size to prove
its safety. Moreover, from the data of the efficacy
evaluation, the degree of improvement of neurological
function of OMAs transplantation showed no advantages compared with the transplantation of OECs
alone.
In 2013, Tabakow et al. [38] conducted a phase I
clinical trial of autologous OECs transplantation in
patients with complete SCI. A total of 6 SCI patients
were included, 3 of which were in the transplantation
group. The cell cultures that Tabakow isolated from
the patient’s autologous olfactory mucosa were mainly
OECs and ONFs. Without further purification, the
percentage of S100 positive cells in the cultures was
only 10%~25.7%. Tabakow et al. [39] then obtained
olfactory bulbs from a patient with sinus disease who
underwent an intracranial surgery. The OEC concentration was 16%, and the autologous spinal cord
transplantation was performed in combination with
peripheral nerve bridging materials. The patient’s
neurological function was significantly enhanced
compared to the 3 OEC transplant recipients who
received this from mucosal origin. In the transplant
operation, the researchers used a micro pump and a
microscopic operating system to inject multiple points
in the Matrix 1. This may cause secondary damage to
the spinal cord. In addition, the number of cases in the
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Table 1 Keywords of EMBASE, Cochrane Library and PubMed.
EMBASE
#1 'olfactory ensheathing cell'/exp OR 'ensheathing cells':ab,ti OR 'olfactory bulb cell':ab,ti OR 'Olfactory ensheathing glia':ab,ti
OR 'ensheathing cell':ab,ti OR 'Olfactory Cortex cell':ab,ti OR 'olfactory cell':ab,ti OR 'olfactory bulb ensheathing cell line':ab,ti OR
'olfactory nerve ensheathing cells':ab,ti OR 'olfactory schwann cell':ab,ti OR 'schwann cells of the olfactory nerve':ab,ti OR 'OECs':ab,ti
#2 'spinal cord injury'/exp OR 'spinal cord trauma':ab,ti OR 'cord trauma, spinal':ab,ti OR 'cord traumas, spinal':ab,ti OR 'spinal cord
traumas':ab,ti OR 'trauma, spinal cord':ab,ti OR 'traumas, spinal cord':ab,ti OR 'injuries, spinal cord':ab,ti OR 'cord injuries, spinal':ab,ti
OR 'cord injury, spinal':ab,ti OR 'injury, spinal cord':ab,ti OR 'spinal cord injury':ab,ti OR 'myelopathy, traumatic':ab,ti OR 'myelopathies,
traumatic':ab,ti OR 'traumatic myelopathies':ab,ti OR 'traumatic myelopathy':ab,ti OR 'spinal cord transection':ab,ti OR 'cord transection,
spinal':ab,ti OR 'laceration, spinal cord':ab,ti OR 'lacerations, spinal cord':ab,ti OR 'spinal cord lacerations':ab,ti OR 'post-traumatic
myelopathy':ab,ti OR 'myelopathies, post-traumatic':ab,ti OR 'myelopathy, post-traumatic':ab,ti OR 'post-traumatic myelopathies':ab,ti
OR 'spinal cord contusion':ab,ti OR 'contusion, spinal cord':ab,ti OR 'contusions, spinal cord':ab,ti OR 'cord contusion, spinal':ab,ti OR
'cord contusions, spinal':ab,ti OR 'spinal cord contusions':ab,ti OR 'injured spinal cord':ab,ti OR 'spinal cord hemisection':ab,ti OR 'spinal
compression':ab,ti
#3 'human':ab,ti OR 'patients':ab,ti
#1 AND #2 AND #3

Cochrane Library
#1 MeSH descriptor: [Spinal Cord Injuries] explode all trees
#2 Spinal Cord Trauma:ti,ab,kw or Myelopathy, Traumatic:ti,ab,kw or Spinal Cord Transection:ti,ab,kw or Spinal Cord Laceration:ti,ab,kw
or Post-Traumatic Myelopathy:ti,ab,kw (Word variations have been searched)
#3 #1 AND #2
#4 olfactory ensheathing cell:ti,ab,kw or olfactory bulb cell:ti,ab,kw or Olfactory ensheathing glia:ti,ab,kw or olfactory schwann cell:ti,ab,kw
or OECs:ti,ab,kw (Word variations have been searched)
#5 #3 and #4

PubMed
Search olfactory ensheathing cell[Title/Abstract]) OR ensheathing cells[Title/Abstract]) OR olfactory bulb cell[Title/Abstract]) OR
Olfactory ensheathing glia[Title/Abstract]) OR ensheathing cell[Title/Abstract]) OR Olfactory Cortex cell[Title/Abstract]) OR olfactory
cell[Title/Abstract]) OR olfactory bulb ensheathing cell line[Title/Abstract]) OR olfactory nerve ensheathing cells[Title/Abstract]) OR
olfactory schwann cell[Title/Abstract]) OR schwann cells of the olfactory nerve[Title/Abstract]) OR OECs[Title/Abstract]) AND (("Spinal
Cord Injuries"[Mesh]) OR Spinal Cord Trauma[Title/Abstract]) OR Cord Trauma, Spinal[Title/Abstract]) OR Cord Traumas, Spinal[Title/
Abstract]) OR Spinal Cord Traumas[Title/Abstract]) OR Trauma, Spinal Cord[Title/Abstract]) OR Traumas, Spinal Cord[Title/Abstract])
OR Injuries, Spinal Cord[Title/Abstract]) OR Cord Injuries, Spinal[Title/Abstract]) OR Cord Injury, Spinal[Title/Abstract]) OR Injury,
Spinal Cord[Title/Abstract]) OR Spinal Cord Injury[Title/Abstract]) OR Myelopathy, Traumatic[Title/Abstract]) OR Myelopathies,
Traumatic[Title/Abstract]) OR Traumatic Myelopathies[Title/Abstract]) OR Traumatic Myelopathy[Title/Abstract]) OR Spinal Cord
Transection[Title/Abstract]) OR Cord Transection, Spinal[Title/Abstract]) OR Cord Transections, Spinal[Title/Abstract]) OR Spinal Cord
Transections[Title/Abstract]) OR Transection, Spinal Cord[Title/Abstract]) OR Transections, Spinal Cord[Title/Abstract]) OR Spinal Cord
Laceration[Title/Abstract]) OR Cord Laceration, Spinal[Title/Abstract]) OR Cord Lacerations, Spinal[Title/Abstract]) OR Laceration,
Spinal Cord[Title/Abstract]) OR Lacerations, Spinal Cord[Title/Abstract]) OR Spinal Cord Lacerations[Title/Abstract]) OR Post-Traumatic
Myelopathy[Title/Abstract]) OR Myelopathies, Post-Traumatic[Title/Abstract]) OR Myelopathy, Post-Traumatic[Title/Abstract]) OR Post
Traumatic Myelopathy[Title/Abstract]) OR Post-Traumatic Myelopathies[Title/Abstract]) OR Spinal Cord Contusion[Title/Abstract]) OR
Contusion, Spinal Cord[Title/Abstract]) OR Contusions, Spinal Cord[Title/Abstract]) OR Cord Contusion, Spinal[Title/Abstract]) OR
Cord Contusions, Spinal[Title/Abstract]) OR Spinal Cord Contusions[Title/Abstract]) OR Injured spinal cord[Title/Abstract]) OR Spinal
cord Hemisection[Title/Abstract]) OR Spinal compression[Title/Abstract]) AND ((human[Title/Abstract]) OR patients[Title/Abstract])

Fig. 1

Literature publication trend chart.

Tabakow’s experiment is very small, and there is no
further large-scale study. Thus, the conclusions drawn
are still not repeatable.
In 2005, Feron et al. [36] performed a single-blind
phase I clinical trial of autologous OECs transplantation
in 6 patients with SCI, and 3 patients in the transplantation group. The results indicated that it was
safe for autologous OECs transplantation within 1 year.
In the grafts prepared in this clinical trial, the positive
Journal of Neurorestoratology
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Table 2 Features of included studies.
Reference

Source

Injection site

Dose

Volume, points

Wu, J et al. [12]
Zhang, Z C et al. [13]

fetal OECs

rostral and caudal ends of the lesions

5 × 105

25 μL/point, 2

Zhang, L et al. [14]

fetal OECs

Group A：the border of the superior part of
lesions and normal spinal cord
Group B: the either sites of the lesions

NA

Group A: 50 μL/point, 1
Group B: 50 μL/
2~4 points, 2~5

Liu, C et al. [15]

fetal OECs

the border of lesions and normal spinal cord

106

100 μL (total), multiple

Zheng, Z C et al. [16–18]

fetal OECs

upper or lower injured region and left or right
normal spinal cord

(1~4) × 106

50 μL/2~5 points, 2~5

Huang, H et al. [19–26]
Chen, L et al. [11, 27, 28]

fetal OECs

rostral and caudal ends of the lesion

106

25 μL/point, 2

Dong, W et al. [29]

fetal OECs

both posterior horns of spinal cord 0.5 cm distal and
proximal to SCI area

8 × 105

10 μL/point, 4

Bao, G F et al. [30]

fetal OECs

multiple points of the cross between spinal cord
injury and normal spinal cord

5 × 105

25 μL (total), multiple

Rao, Y et al. [31]

fetal OECs

the border between lesions and normal spinal cord

(2~5) × 106

50 μL/2~5 points, 2~5

Rao, Y et al. [32]

autologous
OECs

local anesthesia, MR-guided injection to the
lesion tail

8 × 107

2 mL/6 points*, 6

Rao, Y et al. [33]

autologous
OECs

the border between lesions and normal spinal cord

2 × 106

40~50 μL/4~5 points, 4~5

Lima, C et al. [34, 35]

OMAs

parenchyma

NA

NA

Feron, F et al. [36]
Mackay-Sim, A et al. [37]

autologous
OECs

Matrix 1

(1.2~2.8) × 108

1.1 μL, 270~630

Tabakow, P et al. [38]

autologous
OECs+ONFs

Matrix 2

1.8 × 106~
2.12 × 107

60~106 μL/
20~46 points, 20~46

NA, not applicable. *, two sets of injections per week, lasted for 4 weeks. OMAs, contain neural stem cells (NSCs) and OECs. ONFs,
olfactory nerve fibroblasts. Matrix 1, a five by three grid of injection sites was regularly arrayed rostral and caudal to the injured spinal
cord and less regularly than shown through the damaged cord. Rows were 5 mm apart and columns were 1 mm apart where possible.
Matrix 2, consisted of four to five rows, 2 mm apart. The posterolateral sulcus was chosen as the main entry point for cell microinjection.

cells of S100 and glial fibrillary acidic protein (GFAP)
were > 95%, and the p75NTR positive cells ranged
from 76% to 88%. In the transplant operation, the
cells were injected at a depth of 4 mm by means of
Matrix 2. Mackay-Sim [37] has followed the patients
for 3 years. Clinical assessments included medical,
psychosocial, radiological, as well as specialized tests
of neurological and functional deficits. Unfortunately,
except for 1 patient with improved sensory function,
the remaining patients had no significant neurological
recovery.
The above tests are all clinical trials of autologous
olfactory mucosa-derived OECs for the treatment of
chronic SCI. OECs from autologous sources have
no immunological rejection defects. Thus, they are
considered to be one of the best sources of cells for
spinal cord restoration. However, there is no uniform
standard of autologous OECs culture preparation

and transplantation procedures. The sample size is
only 58 cases in total, which shows no significant
neurological restoration.
Most Chinese clinical trials use human fetal OECs
with large sample sizes. Several clinical trials showed
the efficacy of those fetal OECs. These clinical studies
use standard fetal OECs, unified transplantation
methods and pathways that are in line with the
recommendations of The Chinese Clinical Guidelines for
Neurorestoration Cell Therapy [9] and The Clinical Cell
Therapy Guidelines for Neurorestoration [10].

3

3.1

Clinical efficacy of fetal OECs in the
treatment of chronic SCI
Eligibility criteria

To further understand the efficacy of fetal OECs for
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the treatment of chronic SCI, the investigators included
clinical studies that met the two guidelines: (1) patients
with chronic SCI were enrolled in the study and
received fetal OECs for transplantation; (2) reported
American Spinal Injury Association (ASIA) motor score,
light score, and pinprick score; (3) the transplantation
method is parenchymal injection at the junction of
the lesion and/or the upper and lower normal tissues;
(4) single dose is (1~2) × 106 OECs; (5) single injection
volume is less than 25 μL.
Two researchers carefully reviewed all the literatures
to determine the relevant clinical trials. In order to
avoid duplication of statistics, the researchers confirmed
the time of the clinical trial, the research unit and the
follow-up periods, and avoided the literature containing
the duplicate data. Finally, these data was verified by
a third party. For different literatures from a same
clinical trial, we included the largest sample size or
the latest published literature (Table 2 and Table 3).
3.2 Document quality evaluation
The included literatures recorded the ASIA scores
before and after the transplantation. The pre-transplant
neurological status was classified as the exposed group,
and the neurological status after transplantation was
classified as non-exposed group. All literatures were
evaluated by two investigators using the modified
Newcastle-Ottawa Scale (NOS). The quality of the
literatures were determined after the two researchers
reached a unanimous agreement (Table 3).

3.3

Meta analysis

The first author was responsible for data statistics.
The AISA motor score, the light touch score and the
pinprick score were analyzed using the Review
Manager 5.3 program for the two follow-up phases.
Since the ASIA score is a measurement data, the
weighted mean difference (WMD; 95% CI) was used
as the statistical analysis amount. When I2 < 50% and
P > 0.1, the results were considered to be homogenous,
and the fixed effect model was selected. If I2 > 50%, P <
0.1, it was considered no homogeneity in each study,
then a random effects model was used. If the source of
heterogeneity could not be judged, no meta-analysis
was performed.
3.4
3.4.1

Results
Short-term efficacy outcome

Heterogeneity test showed that the short-term
functional changes of motor, light touch and pinprick
scores were homogenous in each study after transplantation (motor score, I2 = 0%, P = 0.61; light touch
score, I2 = 24%, P = 0.26; pinprick score, I2 = 0%, P = 0.45).
Analysis using a fixed effect model suggested that the
differences in the functional scores before and after
OECs transplantation were statistically significant
[motor score, WMD = 4.52, 95% CI (2.00, 7.03), P = 0.0004;
light touch score, WMD = 8.56, 95% CI (5.84, 11.28),
P < 0.00001; pinprick score, WMD = 9.54, 95% CI (6.81,
12.27), P < 0.00001]. This indicated that fetal OECs

Table 3 Fetal OECs efficacy evaluation literature and document quality evaluation.
Author ,Year

Operation time

Sample
size

SCI to
implant

Object
selection

Follow up

Comparability

Result
evaluation Score

A

B

C

D

E

F

G

H

Wu, J et al., 2012 [12]

1/2004‒12/2004

11

6~42 months

12~18 months

0

0

1

1

1

0

1

1

5

Zheng, Z C et al., 2008 [17]

6/2004‒6/2007

114

> 6 months

2~4 weeks

1

1

1

1

1

0

0

1

6

Zheng, Z C et al., 2013 [18]

7/2009‒7/2010

43

> 6 months

3~8 weeks

1

1

1

1

1

0

0

1

6

Huang, H et al., 2006 [23]

11/2001‒1/2004

300

6 months~
18 years

2~8 weeks

1

1

1

1

1

0

0

1

6

Huang, H et al., 2012 [22]*

NA

108

NA

3.47 ± 1.12 years

1

1

1

1

1

0

1

1

7

Dong, W et al., 2013 [29]

9/2005–3/2010

24

> 6 months

average of 3.2 years 0

0

1

1

1

0

1

1

5

*, confirmed with the author, this document is the final long-term follow-up data. A, selection of exposed group; B, selection of non-exposed
group; C, determination of subject acceptance fetal OECs transplantation; D, the patient did not show the expected test results before the
start of the trial; E, the exposed group is comparable to the non-exposed group; F, blind method; G: follow-up time (> 6 months);H, loss of
visit rate < 10%.
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transplantation significantly improved the movement
and tactile function of SCI patients (Fig. 2).
3.4.2

Long-term efficacy outcome

Heterogeneity test showed that long-term changes
of motor function, light touch and pinprick were
homogenous in each study after transplantation (motor
score, I2 = 0%, P = 0.90; light touch score, I2 = 0%, P = 0.79;
pinprick score, I2 = 0%, P = 0.71). Analysis using a fixed
effect model suggested that the scores of light touch
and pinprick functional scores in patients with chronic
SCI before and after OECs transplantation were
statistically significant [light touch score, WMD = 6.92,
95% CI (1.33, 12.52), P = 0.02; pinprick score, WMD =
7.48, 95% CI (2.01,12.96), P = 0.007]. This shows that
OECs transplantation significantly improved the longterm light touch and pinprick functions in SCI patients.
There was no statistically significant differences in
motor function scores [WMD = 2.53, 95% CI (–1.20, 6.25),
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P = 0.18], indicating that OECs did not significantly
improve long-term motor function in patients with
chronic SCI. A meta-analysis of exercise, light touch
and pinprick functions in patients with chronic OECs
after long-term follow-up is shown in Fig. 3.

4

Discussion

Up till now, there are 4 countries in the world to carry
out clinical trials of OECs transplantation for chronic
SCI patients. The OECs’ sources include: fetal OECs
which are obtained from human fetal olfactory bulbs,
OMAs and/or autologous OECs obtained from
autologous nasal mucosa. Since the transplantation
methods and observation of efficacy indicators are
different in these clinical trials, it is impossible to
compare the efficacy of three different kinds of OECs.
The morphological and immunohistochemical properties of OECs from the olfactory mucosa and the

Fig. 2 Short-term ASIA score of motor (A), light touch (B) and pinprick (C). (1) Complete paraplegia group; (2) incomplete paralysis group;
(3)injured for 6 months to 2 years; (4) injured for > 2 years.

76
olfactory bulb are consistent. Moreover, OECs derived
from their own sources have no defects in immune
rejection and are thought to be the best cells for restoring
the spinal cord function. However, these OECs in
previous clinical trials have no uniform culture standards
and transplantation specification. The trials have low
reproducibility due to a small number of sample cases
resulting in a lack of the efficacy of credible results.
Perhaps due to these reasons, the guidelines do not
recommend their protocols.
Fetal OECs derived from allogeneic sources are the
first neurorestorative cells to be used in clinical trials.
After rigorous screening and eliminating the repeated
data, this study concluded that the total sample of
clinical trials of fetal OECs in the treatment of chronic
SCI reached 512, which basically met the sample
requirements to prove the safety of clinical application.
For the preparation and quality control of fetal
OECs, Chinese Association of Neurorestoratology recommended the culture method and quality control
standards of fetal OECs based on the previous clinical
investigations [40]. By applying the standard protocol,
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the activity and purity of OECs could reach 95% and
90%, respectively. This is the only standard set for the
OECs in the world that not only provides the basis
for strict regulation of cell culture preparation in
previous clinical studies, but also promotes the safety,
efficacy and reproducibility of fetal OECs for clinical
neurorestorative therapy for the future.
The investigators performed an analysis of six
standard-compliant clinically studies of fetal OECs in
the treatment of chronic SCI. The results showed that
the short-term neurological function was significantly
improved as evident by the motor score increased by
4.52 points (2.00, 7.03), the light touch score increased
by 8.56 points (5.84, 11.28), and the pinprick score
increased by 9.54 points (6.81, 12.27). Huang et al. [23]
have hypothesized that the rapid functional recovery
may be due to the mechanism of unmasking the
quiescent axons that are still alive but not functioning.
In the long-term efficacy analysis, the light touch
score increased by 6.92 points (1.33, 12.52) and the
pinprick score increased by 7.48 points (2.01, 12.96).
However, the motor score increased by an average of

Fig. 3 Long-term ASIA score of motor (A), light touch (B) and pinprick (C). (1) Complete paraplegic group; (2) incomplete paralysis
group; (3) foreign group; (4) good domestic rehabilitation group; (5) poor domestic rehabilitation group.
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2.53 points (–1.20, 6.25), suggesting that there was no
significant difference in efficacy compared with the
cell pre-operation. There are no experimental studies
or systematic reviews available so far to identify this
problem and analyze the cause of the decline in motor
functions except Huang’s study [24].
Huang et al. [24] found that the group of poor rehabilitation had lower scores of neurological functions
compared with the group of good rehabilitation (P <
0.01). One of the reasons is that intensive neurorehabilitation can enhance the neurological functional recovery
including motor function after OEC therapy. This
suggests that it is necessary to combine with long-term
rehabilitation exercise after cell transplantation or other
neurorestorative therapies to improve the neurological
functions. Tabakow et al. [38] said that a combination
of rehabilitation efforts after cell transplantation is
beneficial for chronic SCI, and future controlled trials
need to include a lengthy and intensive rehabilitation
protocol to enhance the efficacy of the cell therapy. It
appears that when OECs are gradually inactivated, the
structure of nerves may not be restored any further.
Thus, if the patients don’t maintain enough rehabilitation exercise, their motor function performance
will decrease.
In addition, the immunological problems of fetal
OECs cannot be ignored either. Chronic immune
rejection may also lead to poor long-term efficacy. In
order to improve the survival rate of transplanted cells
and reduce the graft host response, Chen et al. [41] had
performed human leukocyte antigen (HLA) matching
and transplanted OECs in a group of patients with
amyotrophic lateral sclerosis (ALS) and compared them
with unmatched patients. HLA matching can further
delay the progressive deterioration of ALS patients.
However, due to the small sample size or lack of longterm follow-up, there was no significant difference
found between these groups.
In terms of transplantation, except Rao’s trial [32]
which used MR-guidance for injections, the other trials
were performed by spinal surgery which is traumatic
and requires high physical status of the patients.
Several trials on assessing safety have found that
adverse events in OECs transplantation are closely
related to spinal surgery. In order to reduce the adverse
reactions, future clinical research should carefully
grasp the preoperative indications and try to explore
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a minimally invasive and effective transplantation
method. A large number of animal studies have shown
that intranasal delivery is a safe, minimally invasive
and effective method for cell transplantation [42–45].
However, it has not been reported in clinical practices.
Recently, the multi-center randomized controlled
clinical trial of OECs intranasal delivery, led by the
Chinese Association of Neurorestoratology, is carried
out in China. The results of relevant research are
awaited.
The clinical trials in this systematic review are selfcontrolled. Time window of these trails is chronic or
squealed. Therefore, the interference of spinal nerve
self-repair can be ruled out, and the clinical efficacy of
OECs is confirmed. On the other hand, many scholars
consider that, in the chronic phase, a large number of
neurons are atrophied and more scars are present in
the traumatized spinal cord area. In such cases, the
time for transplantation and the time window could be
advanced. Khankan et al. [7] found that, in the acute
phase, OECs can survive in SCI area for 8 weeks and
prevents the acute inflammatory responses to reduce
further damage of neurons. In other experiments,
Resnick et al. [46] indicated that transplantation of
OECs is not effective immediately after spinal cord
contusion. Plant et al. [47] believed that the transplant
effects in rats 7 days after injury was better than that
of 30 minutes after injury. In summary, the best time
window for OECs transplantation needs to be further
explored.
In the design of the treatment, Huang et al. [24] proposed that if the neurological function is stable for 1.5
to 2 years, the patient could receive the transplantation
again. For the patients with progressive deterioration a
year after transplantation, a secondary transplantation
is an optimal choice. A design of fractional injection
therapy was also used in Rao’s trial [32]. However,
since the above two studies are not RCT tests, it is
still necessary to explore the design of the treatment
further to improve the techniques.
In conclusion, this study systematically reviewed
the sources of cell, path of transplantation, the doses,
the time window, and the design of the treatment in
the clinical studies of OECs transplantation for chronic
SCI. In all circumstances, OEC or other neurorestorative
therapies should combine with intensive neurorehabilitation. It is hoped that this review could reduce
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the gap between the two major guidelines. However,
there are still many more problems and bottle necks
to be solved for the OECs clinical transplantation in
the future.
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